Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2012

Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, et al. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012;7(6):e38881.

Limbach AL, Goyal A. Adult rhabdomyoma: A challenging diagnosis on cytology. Cytojournal. 2012;9:20.

Cushing M, Kawaguchi K, Friedman KD, Mark T. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion. 2012;52(7):1535-41.

Zhang T, DeSimone RA, Jiao X, F Rohlf J, Zhu W, Gong QQ, et al. Host genes related to paneth cells and xenobiotic metabolism are associated with shifts in human ileum-associated microbial composition. PLoS One. 2012;7(6):e30044.

Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012;120(5):1095-106.

Hedhli N, Falcone DJ, Huang B, Cesarman-Maus G, Kraemer R, Zhai H, et al. The annexin A2/S100A10 system in health and disease: emerging paradigms. J Biomed Biotechnol. 2012;2012:406273.

Kim J, Kim W-, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle. 2012;11(6):1123-30.

Kim J, Keay SK, You S, Loda M, Freeman MR. A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2. PLoS One. 2012;7(12):e50392.

Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep. 2012;13(2):122-35.

Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget. 2012;3(6):651-63.